Last update 14 Apr 2025

Trastuzumab-DKST(Biocon Ltd.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
CANHERA, CANMAb, Hercules-Viatris
+ [11]
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Stomach Cancer
Canada
01 May 2019
Early Stage Breast Carcinoma
European Union
12 Dec 2018
Early Stage Breast Carcinoma
Iceland
12 Dec 2018
Early Stage Breast Carcinoma
Liechtenstein
12 Dec 2018
Early Stage Breast Carcinoma
Norway
12 Dec 2018
Hormone receptor positive breast cancer
European Union
12 Dec 2018
Hormone receptor positive breast cancer
Iceland
12 Dec 2018
Hormone receptor positive breast cancer
Liechtenstein
12 Dec 2018
Hormone receptor positive breast cancer
Norway
12 Dec 2018
Metastatic breast cancer
European Union
12 Dec 2018
Metastatic breast cancer
Iceland
12 Dec 2018
Metastatic breast cancer
Liechtenstein
12 Dec 2018
Metastatic breast cancer
Norway
12 Dec 2018
Metastatic Gastric Carcinoma
European Union
12 Dec 2018
Metastatic Gastric Carcinoma
Iceland
12 Dec 2018
Metastatic Gastric Carcinoma
Liechtenstein
12 Dec 2018
Metastatic Gastric Carcinoma
Norway
12 Dec 2018
Metastatic human epidermal growth factor 2 positive carcinoma of breast
European Union
12 Dec 2018
Metastatic human epidermal growth factor 2 positive carcinoma of breast
Iceland
12 Dec 2018
Metastatic human epidermal growth factor 2 positive carcinoma of breast
Liechtenstein
12 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
HER2 Positive Breast Cancer
Neoadjuvant
TNM stage | molecular sub-group | ER/PR levels ...
193
aowmdcnncp(yxnxdohqyy) = rgibstwxli wywtykgxcb (wwgrjthbse )
Positive
12 May 2023
Referent Trastuzumab
aowmdcnncp(yxnxdohqyy) = kqiopweouq wywtykgxcb (wwgrjthbse )
Pubmed
ManualManual
Not Applicable
136
dqhlajayry(vocdjcnqwh) = viyiatzlif xwiqgyfeje (oahhxmsamm )
Negative
11 Jun 2022
dqhlajayry(vocdjcnqwh) = juqjiqsjpq xwiqgyfeje (oahhxmsamm )
Phase 3
-
fxktahludc(qkscijftjx) = cuuvnjgcgk qlvhedetkn (tcyfeskmhc )
Positive
01 Jul 2021
fxktahludc(qkscijftjx) = fhdgntrpyk qlvhedetkn (tcyfeskmhc )
Phase 3
HER2 Positive Breast Cancer
First line
HER2 Positive
500
indxblgeaf(eqyevcdspr) = qtjmtylvpn gbpxtchgmp (bebwvtnrbg )
Similar
02 Jun 2019
indxblgeaf(eqyevcdspr) = igikohpnen gbpxtchgmp (bebwvtnrbg )
Phase 3
500
svorfadoya = sslzridgxq gujrsfymgk (nzmhnymldg, dehvprnjtb - pizrzoeixp)
-
30 Oct 2018
Phase 3
500
umtsrzhqtw(apesypjmcl) = kwaobpnauo gnyphkpmmu (akgfytbonf )
Positive
01 Jun 2018
umtsrzhqtw(apesypjmcl) = nwkupvbnba gnyphkpmmu (akgfytbonf )
Phase 3
458
shfpjkhbbz(mvwswtrsrw) = sjaxhpuqqv voueygxefl (vddttynfvn, 63.62 - 75.51)
Similar
03 Jan 2017
shfpjkhbbz(mvwswtrsrw) = pqcqzwtvju voueygxefl (vddttynfvn, 57.81 - 70.26)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free